Curis (CRIS) Earns Daily Coverage Optimism Rating of 0.13

News coverage about Curis (NASDAQ:CRIS) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Curis earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 47.24143922853 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

Curis (CRIS) opened at 1.71 on Tuesday. The company has a 50-day moving average price of $1.98 and a 200-day moving average price of $2.32. Curis has a one year low of $1.60 and a one year high of $3.72. The stock’s market cap is $245.85 million.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.01. The business had revenue of $2.10 million during the quarter, compared to the consensus estimate of $2.08 million. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. The company’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.09) earnings per share. On average, analysts anticipate that Curis will post ($0.40) earnings per share for the current year.

A number of research analysts recently commented on CRIS shares. Zacks Investment Research downgraded Curis from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Cowen and Company reissued a “buy” rating on shares of Curis in a report on Monday, May 15th. ValuEngine raised Curis from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, BidaskClub downgraded Curis from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $5.88.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Insider Buying and Selling by Quarter for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply